Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Therapy With Direct-Acting Antiviral Agents for Hepatitis C in Liver Transplant Recipients.

Nogueras López F, López Garrido A, Ortega Suazo EJ, Vadillo Calles F, Valverde López F, Espinosa Aguilar MD.

Transplant Proc. 2018 Mar;50(2):631-633. doi: 10.1016/j.transproceed.2017.09.057.

PMID:
29579872
2.

Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.

Huang AC, Mehta N, Dodge JL, Yao FY, Terrault NA.

Hepatology. 2018 Aug;68(2):449-461. doi: 10.1002/hep.29855. Epub 2018 May 16.

3.

Predictors of hepatitis C virus recurrence after living donor liver transplantation: Mansoura experience.

Abdel-Wahab M, Abdel-Khalek EE, El-Gilany AH, Yassen AM, Al-Shobari M, Shiha U, Ali M, Sadani M, Salah T, Sultan AM, Elghawalby AN, Elmorshedi M, Al-Refaey AK, Abdalla U.

Arab J Gastroenterol. 2017 Sep;18(3):151-155. doi: 10.1016/j.ajg.2017.09.006. Epub 2017 Sep 22.

PMID:
28958486
4.

Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver transplantation: a real-world cohort.

Bernuth S, Grimm D, Vollmar J, Darstein F, Mittler J, Heise M, Hoppe-Lotichius M, Galle PR, Lang H, Zimmermann T.

Drug Des Devel Ther. 2017 Jul 12;11:2131-2138. doi: 10.2147/DDDT.S139837. eCollection 2017.

5.

Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study.

Salcedo M, Prieto M, Castells L, Pascasio JM, Montero Alvarez JL, Fernández I, Sánchez-Antolín G, González-Diéguez L, García-Gonzalez M, Otero A, Lorente S, Espinosa MD, Testillano M, González A, Castellote J, Casafont F, Londoño MC, Pons JA, Molina Pérez E, Cuervas-Mons V, Pascual S, Herrero JI, Narváez I, Vinaixa C, Llaneras J, Sousa JM, Bañares R.

Transpl Int. 2017 Oct;30(10):1041-1050. doi: 10.1111/tri.12999. Epub 2017 Jul 27.

6.

Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.

Zanetto A, Shalaby S, Vitale A, Mescoli C, Ferrarese A, Gambato M, Franceschet E, Germani G, Senzolo M, Romano A, Angeli P, Rugge M, Farinati F, Forton DM, Cillo U, Burra P, Russo FP.

Liver Transpl. 2017 Sep;23(9):1103-1112. doi: 10.1002/lt.24790.

7.

Efficacy and Safety of Therapy With Simeprevir and Sofosbuvir in Liver Transplant Recipients Infected by Hepatitis C Virus Genotype 4: Cohort Spanish Society of Liver Transplantation Cohort.

Sanchez Antolin G, Testillano M, Pascasio JM, Narvaez Rodriguez I, Prieto M, Otero A, Herrero JI, Londoño M, Fernandez Vazquez I, Castells L; Spanish Society of Liver Transplantation Study Group Collaborating Group.

Transplant Proc. 2016 Nov;48(9):3013-3016. doi: 10.1016/j.transproceed.2016.08.034.

PMID:
27932134
8.

Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence.

Song AT, Sobesky R, Vinaixa C, Dumortier J, Radenne S, Durand F, Calmus Y, Rousseau G, Latournerie M, Feray C, Delvart V, Roche B, Haim-Boukobza S, Roque-Afonso AM, Castaing D, Abdala E, D'Albuquerque LA, Duclos-Vallée JC, Berenguer M, Samuel D.

World J Gastroenterol. 2016 May 14;22(18):4547-58. doi: 10.3748/wjg.v22.i18.4547.

9.

Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation.

Vitale A, Spolverato G, Burra P, De Feo TM, Belli L, Donato F, Baroni GS, Marianelli T, Picciotto A, Toniutto P, Bhoori S, Passigato N, Lucà MG, Russo FP, Cillo U, Fagiuoli S; Liver Transplantation NITp working group.

Transpl Int. 2015 Sep;28(9):1055-65. doi: 10.1111/tri.12591. Epub 2015 Apr 30.

Supplemental Content

Loading ...
Support Center